Of note, the inhibition of the CD47-SIRPα signaling pathway by rituximab alone in patients of follicular lymphoma led to anemia, and this side effect could be mitigated by 5F9 (a macrophage immune checkpoint inhibitor) [165,166], illustrating that combining rituximab for blocking CD47 and 5F9 for attenuating anemia could be an example of optimized antibody-dependent cellular phagocytosis. This evidence concerns the gene CD47 and anemia (phenotype).